Clinical trials
Recruiting Phase 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 4 |
| 2023 | 2 |
| 2024 | 8 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 25 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 5 |
| St. Petersburg State Pavlov Medical University | 3 |
| Fred Hutchinson Cancer Center | 2 |
| Masonic Cancer Center, University of Minnesota | 2 |
| Novartis Pharmaceuticals | 2 |
| Center for International Blood and Marrow Transplant Research | 1 |
| City of Hope Medical Center | 1 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 1 |
| Imperial College London | 1 |
| Medical College of Wisconsin | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 25 |
| Leukemia, Myeloid, Acute | 15 |
| Myelodysplastic Syndromes | 13 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 |
| Lymphoma, Non-Hodgkin | 7 |
| Myeloproliferative Disorders | 7 |
| Leukemia, Biphenotypic, Acute | 6 |
| Primary Myelofibrosis | 6 |
| Hodgkin Disease | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
Trials
Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.